{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:22:41Z","timestamp":1788974561464,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank"},{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A series of (<jats:italic>Z<\/jats:italic>)-<jats:italic>N<\/jats:italic>-(adamantan-1-yl)-3,4-diarylthiazol-2(3<jats:italic>H<\/jats:italic>)-imines (<jats:bold>5a-r<\/jats:bold>) was synthesized via condensation of 1-(adamantan-1-yl)-3-arylthioureas (<jats:bold>3a-c<\/jats:bold>) with various aryl bromomethyl ketones (<jats:bold>4a-f<\/jats:bold>). The structures of the synthesized compounds were characterized by <jats:sup>1<\/jats:sup>H NMR, <jats:sup>13<\/jats:sup>C NMR and by X-ray crystallography. The in vitro inhibitory activities of the synthesized compounds were assessed against a panel of Gram-positive and Gram-negative bacteria, and pathogenic fungi. Compounds <jats:bold>5c<\/jats:bold>, <jats:bold>5g<\/jats:bold>, <jats:bold>5l<\/jats:bold>, <jats:bold>5m<\/jats:bold>, and <jats:bold>5q<\/jats:bold> displayed potent broad-spectrum antibacterial activity, while compounds <jats:bold>5a<\/jats:bold> and <jats:bold>5o<\/jats:bold> showed activity against the tested Gram-positive bacteria. Compounds <jats:bold>5b<\/jats:bold>, <jats:bold>5l<\/jats:bold> and <jats:bold>5q<\/jats:bold> displayed potent antifungal activity against <jats:italic>Candida albicans<\/jats:italic>. In addition, the synthesized compounds were evaluated for anti-proliferative activity towards five human tumor cell lines. The optimal anti-proliferative activity was attained by compounds <jats:bold>5e<\/jats:bold> and <jats:bold>5k<\/jats:bold> which showed potent inhibitory activity against all the tested cell lines. Molecular docking analysis reveals that compounds <jats:bold>5e<\/jats:bold> and <jats:bold>5k<\/jats:bold> can occupy the positions of NAD cofactor and the histone deacetylase inhibitor EX527 at the active site of SIRT1 enzyme.<\/jats:p>","DOI":"10.1038\/s41598-022-25390-0","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:46:12Z","timestamp":1670330772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Synthesis and in vitro antibacterial, antifungal, anti-proliferative activities of novel adamantane-containing thiazole compounds"],"prefix":"10.1038","volume":"12","author":[{"given":"Eman T.","family":"Warda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud B.","family":"El-Ashmawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El-Sayed E.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S. M.","family":"Abdelbaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Garcia-Granda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbiah","family":"Thamotharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"El-Emam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"25390_CR1","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.2174\/0929867323666160525114026","volume":"23","author":"K Spilovska","year":"2016","unstructured":"Spilovska, K. et al. Adamantane-a lead structure for drugs in clinical practice. Curr. Med. Chem. 23, 3245\u20133266. https:\/\/doi.org\/10.2174\/0929867323666160525114026 (2016).","journal-title":"Curr. Med. Chem."},{"key":"25390_CR2","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1021\/cr100264t","volume":"113","author":"L Wanka","year":"2013","unstructured":"Wanka, L., Iqbal, K. & Schreiner, P. R. The lipophilic bullet hits the targets: Medicinal chemistry of adamantane derivatives. Chem. Rev. 113, 3516\u20133604. https:\/\/doi.org\/10.1021\/cr100264t (2013).","journal-title":"Chem. Rev."},{"key":"25390_CR3","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/j.ejmech.2011.01.047","volume":"46","author":"J Liu","year":"2011","unstructured":"Liu, J., Obando, D., Liao, V., Lifa, T. & Codd, R. The many faces of the adamantyl group in drug design. Eur. J. Med. Chem. 46, 1949\u20131963. https:\/\/doi.org\/10.1016\/j.ejmech.2011.01.047 (2011).","journal-title":"Eur. J. Med. Chem."},{"key":"25390_CR4","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.2174\/092986710792065027","volume":"17","author":"G Lamoureux","year":"2010","unstructured":"Lamoureux, G. & Artavia, G. Use of the adamantane structure in medicinal chemistry. Curr. Med. Chem. 17, 2967\u20132978. https:\/\/doi.org\/10.2174\/092986710792065027 (2010).","journal-title":"Curr. Med. Chem."},{"key":"25390_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1126\/science.144.3620.862","volume":"144","author":"WL Davies","year":"1964","unstructured":"Davies, W. L. et al. Antiviral activity of 1-adamantamine (amantadine). Science 144, 862\u2013863. https:\/\/doi.org\/10.1126\/science.144.3620.862 (1964).","journal-title":"Science"},{"key":"25390_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/cpt19667138","volume":"7","author":"HA Wendel","year":"1966","unstructured":"Wendel, H. A., Snyder, M. T. & Pell, S. Trial of amantadine in epidemic influenza. Clin. Pharmacol. Therap. 7, 38\u201343. https:\/\/doi.org\/10.1002\/cpt19667138 (1966).","journal-title":"Clin. Pharmacol. Therap."},{"key":"25390_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJM196909112811102","volume":"281","author":"WL Wingfield","year":"1969","unstructured":"Wingfield, W. L., Pollack, D. & Grunert, R. R. Treatment of influenza. The therapeutic efficacy of rimantadine HCl in a naturally occurring influenza A2 respiratory illness in man. N. Engl. J. Med. 281, 579\u2013584. https:\/\/doi.org\/10.1056\/NEJM196909112811102 (1969).","journal-title":"N. Engl. J. Med."},{"key":"25390_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1128\/AAC.22.6.1031","volume":"22","author":"KS Rosenthal","year":"1982","unstructured":"Rosenthal, K. S., Sokol, M. S., Ingram, R. L., Subramanian, R. & Fort, R. C. Tromantadine: Inhibitor of early and late events in herpes simplex virus replication. Antimicrob. Agents Chemother. 22, 1031\u20131036. https:\/\/doi.org\/10.1128\/AAC.22.6.1031 (1982).","journal-title":"Antimicrob. Agents Chemother."},{"key":"25390_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00280-006-0295-5","volume":"59","author":"J Long","year":"2007","unstructured":"Long, J. et al. Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1. Cancer Chemother. Pharmacol. 59, 527\u2013735. https:\/\/doi.org\/10.1007\/s00280-006-0295-5 (2007).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"25390_CR10","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1021\/jm800285f","volume":"51","author":"P Lorenzo","year":"2008","unstructured":"Lorenzo, P. et al. Inhibition of I\u03baB kinase-\u03b2 and anticancer activities of novel chalcone adamantyl arotinoids. J. Med. Chem. 51, 5431\u20135440. https:\/\/doi.org\/10.1021\/jm800285f (2008).","journal-title":"J. Med. Chem."},{"key":"25390_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nchembio.2082","volume":"12","author":"T Han","year":"2016","unstructured":"Han, T. et al. The antitumor toxin CD437 is a direct inhibitor of DNA polymerase \u03b1. Nat. Chem. Biol. 12, 511\u2013515. https:\/\/doi.org\/10.1038\/nchembio.2082 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"25390_CR12","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1002\/ijc.31234","volume":"142","author":"L Dai","year":"2018","unstructured":"Dai, L., Smith, C. D., Foroozesh, M., Miele, L. & Qin, Z. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo. Int. J. Cancer 142, 2153\u20132162. https:\/\/doi.org\/10.1002\/ijc.31234 (2018).","journal-title":"Int. J. Cancer"},{"key":"25390_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.16966\/2473-1846.159","volume":"5","author":"R Kurd","year":"2020","unstructured":"Kurd, R., Ben-Chetrit, E., Karameh, H. & Bar-Meir, M. Compassionate use of opaganib for patients with severe COVID-19. J. Emerg. Dis. Virol. 5, 3. https:\/\/doi.org\/10.16966\/2473-1846.159 (2020).","journal-title":"J. Emerg. Dis. Virol."},{"key":"25390_CR14","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/jac\/dki319","volume":"56","author":"M Protopopova","year":"2005","unstructured":"Protopopova, M. et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J. Antimicrob. Chemother. 56, 968\u2013974. https:\/\/doi.org\/10.1093\/jac\/dki319 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"25390_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bmcl.2009.10.135","volume":"20","author":"E Bogatcheva","year":"2010","unstructured":"Bogatcheva, E. et al. Discovery of dipiperidines as new antitubercular agents. Bioorg. Med. Chem. Lett. 20, 201\u2013205. https:\/\/doi.org\/10.1016\/j.bmcl.2009.10.135 (2010).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"25390_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1517\/13543776.2014.910196","volume":"24","author":"A Leoni","year":"2022","unstructured":"Leoni, A., Locatelli, A., Morigi, R. & Rambaldi, M. Novel thiazole derivatives: A patent review (2008\u20132012. Part 2). Expert Opin. Ther. Pat. 24, 759\u2013777. https:\/\/doi.org\/10.1517\/13543776.2014.910196 (2022).","journal-title":"Expert Opin. Ther. Pat."},{"key":"25390_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ejmech.2015.04.015","volume":"97","author":"A Ayati","year":"2015","unstructured":"Ayati, A., Emami, S., Asadipour, A., Shafiee, A. & Foroumadi, A. Recent applications of 1,3-thiazole core structure in the identification of new lead compounds and drug discovery. Eur. J. Med. Chem. 97, 699\u2013718. https:\/\/doi.org\/10.1016\/j.ejmech.2015.04.015 (2015).","journal-title":"Eur. J. Med. Chem."},{"key":"25390_CR18","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.3390\/molecules26113166","volume":"26","author":"A Petrou","year":"2021","unstructured":"Petrou, A., Fesatidou, M. & Geronikaki, A. Thiazole ring-a biologically active scaffold. Molecules 26, 3166. https:\/\/doi.org\/10.3390\/molecules26113166 (2021).","journal-title":"Molecules"},{"key":"25390_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejmech.2019.03.024","volume":"170","author":"LRP de Siqueira","year":"2019","unstructured":"de Siqueira, L. R. P., de Moraes, G. P. A. T., de Lima, F. L. P., de Melo, R. M. J. B. & Leite, A. C. L. Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues. Eur. J. Med. Chem. 170, 237\u2013260. https:\/\/doi.org\/10.1016\/j.ejmech.2019.03.024 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"25390_CR20","doi-asserted-by":"publisher","first-page":"112016","DOI":"10.1016\/j.ejmech.2019.112016","volume":"188","author":"PC Sharma","year":"2020","unstructured":"Sharma, P. C., Bansal, K. K., Sharma, A., Sharma, D. & Deep, A. Thiazole-containing compounds as therapeutic targets for cancer therapy. Eur. J. Med. Chem. 188, 112016. https:\/\/doi.org\/10.1016\/j.ejmech.2019.112016 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"25390_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ejmech.2015.07.032","volume":"102","author":"NP de S\u00e1","year":"2015","unstructured":"de S\u00e1, N. P. et al. Thiazole compounds with activity against Cryptococcus gattii and Cryptococcus neoformans in vitro. Eur. J. Med. Chem. 102, 233\u2013242. https:\/\/doi.org\/10.1016\/j.ejmech.2015.07.032 (2015).","journal-title":"Eur. J. Med. Chem."},{"key":"25390_CR22","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.bmcl.2013.01.039","volume":"23","author":"LT Maillard","year":"2012","unstructured":"Maillard, L. T. et al. Synthesis and anti-Candida activity of novel 2-hydrazino-1,3-thiazole derivatives. Bioorg. Med. Chem. Lett. 23, 1803\u20131807. https:\/\/doi.org\/10.1016\/j.bmcl.2013.01.039 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"25390_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000142334","volume":"54","author":"C Borelli","year":"2008","unstructured":"Borelli, C. et al. Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi. Chemotherapy 54, 245\u2013259. https:\/\/doi.org\/10.1159\/000142334 (2008).","journal-title":"Chemotherapy"},{"key":"25390_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ejmech.2016.07.062","volume":"123","author":"GM Reddy","year":"2016","unstructured":"Reddy, G. M. et al. Synthesis, antimicrobial activity and advances in structure-activity relationships (SARs) of novel tri-substituted thiazole derivatives. Eur. J. Med. Chem. 123, 508\u2013513. https:\/\/doi.org\/10.1016\/j.ejmech.2016.07.062 (2016).","journal-title":"Eur. J. Med. Chem."},{"key":"25390_CR25","doi-asserted-by":"publisher","first-page":"0142321","DOI":"10.1371\/journal.pone.0142321","volume":"10","author":"M Mohammad","year":"2015","unstructured":"Mohammad, M., Cushman, M. & Seleem, M. N. Antibacterial evaluation of synthetic thiazole compounds in vitro and in vivo in a methicillin-resistant staphylococcus aureus (MRSA) skin infection mouse model. PLoS ONE 10, 0142321. https:\/\/doi.org\/10.1371\/journal.pone.0142321 (2015).","journal-title":"PLoS ONE"},{"key":"25390_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1573406415666190614101253","volume":"16","author":"IP Singh","year":"2020","unstructured":"Singh, I. P., Gupta, S. & Kumar, S. Thiazole compounds as antiviral agents: An update. Med. Chem. 16, 4\u201323. https:\/\/doi.org\/10.2174\/1573406415666190614101253 (2020).","journal-title":"Med. Chem."},{"key":"25390_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/14756366.2018.1550752","volume":"34","author":"CCB Brito","year":"2019","unstructured":"Brito, C. C. B. et al. Synthesis and biological evaluation of thiazole derivatives as LbSOD inhibitors. J. Enzyme Inhib. Med. Chem. 34, 333\u2013342. https:\/\/doi.org\/10.1080\/14756366.2018.1550752 (2019).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"25390_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1124\/jpet.110.172387","volume":"335","author":"Y Liu","year":"2010","unstructured":"Liu, Y. et al. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor. J. Pharmacol. Exp. Ther. 335, 351\u2013361. https:\/\/doi.org\/10.1124\/jpet.110.172387 (2010).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"25390_CR29","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1021\/acschemneuro.0c00093","volume":"11","author":"FH Al-Awadhi","year":"2020","unstructured":"Al-Awadhi, F. H. et al. Largazole is a brain-penetrant class I HDAC inhibitor with extended applicability to glioblastoma and CNS diseases. ACS Chem. Neurosci. 11, 1937\u20131943. https:\/\/doi.org\/10.1021\/acschemneuro.0c00093 (2020).","journal-title":"ACS Chem. Neurosci."},{"key":"25390_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/13543784.2019.1597052","volume":"28","author":"MK Bratt\u00e5s","year":"2019","unstructured":"Bratt\u00e5s, M. K., Reikvam, H., Tvedt, T. H. A. & Bruserud, \u00d8. Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Expert Opin. Investig. Drugs 28, 411\u2013420. https:\/\/doi.org\/10.1080\/13543784.2019.1597052 (2019).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"25390_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/1060028013513009","volume":"48","author":"VA Trinh","year":"2014","unstructured":"Trinh, V. A., Davis, J. E., Anderson, J. E. & Kim, K. B. Dabrafenib therapy for advanced melanoma. Ann. Pharmacother. 48, 519\u2013529. https:\/\/doi.org\/10.1177\/1060028013513009 (2014).","journal-title":"Ann. Pharmacother."},{"key":"25390_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1358\/dot.2020.56.6.3137526","volume":"56","author":"MS Copur","year":"2020","unstructured":"Copur, M. S. Alpelisib to treat breast cancer. Drugs Today 56, 357\u2013363. https:\/\/doi.org\/10.1358\/dot.2020.56.6.3137526 (2020).","journal-title":"Drugs Today"},{"key":"25390_CR33","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1021\/np50118a020","volume":"58","author":"MA Rashid","year":"1995","unstructured":"Rashid, M. A., Gustafson, K. R., Cardellina, J. H. & Boyd, M. R. P. F. A new cytotoxic cyclic peptide from the colonial ascidian Lissoclinum patella. J. Nat. Prod. 58, 594\u2013597. https:\/\/doi.org\/10.1021\/np50118a020 (1995).","journal-title":"J. Nat. Prod."},{"key":"25390_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.617874","volume":"11","author":"NK Ibrahim","year":"2021","unstructured":"Ibrahim, N. K. Ixabepilone: Overview of effectiveness, safety, and tolerability in metastatic breast cancer. Front. Oncol. 11, 617874. https:\/\/doi.org\/10.3389\/fonc.2021.617874 (2021).","journal-title":"Front. Oncol."},{"key":"25390_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2165\/00003495-200868020-00001","volume":"68","author":"P Pronzato","year":"2008","unstructured":"Pronzato, P. New therapeutic options for chemotherapy-resistant metastatic breast cancer: The epothilones. Drugs 68, 139\u2013146. https:\/\/doi.org\/10.2165\/00003495-200868020-00001 (2008).","journal-title":"Drugs"},{"key":"25390_CR36","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1016\/j.bmc.2004.07.033","volume":"12","author":"AA El-Emam","year":"2004","unstructured":"El-Emam, A. A., Al-Deeb, O. A., Al-Omar, M. & Lehmann, J. Synthesis, antimicrobial, and anti-HIV-1 activity of certain 5-(1-adamantyl)-2-substituted thio-1,3,4-oxadiazoles and 5-(1-adamantyl)-3-substituted aminomethyl-1,3,4-oxadiazoline-2-thiones. Bioorg. Med. Chem. 12, 5107\u20135113. https:\/\/doi.org\/10.1016\/j.bmc.2004.07.033 (2004).","journal-title":"Bioorg. Med. Chem."},{"key":"25390_CR37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejmech.2013.07.024","volume":"68","author":"AA El-Emam","year":"2013","unstructured":"El-Emam, A. A., Al-Tamimi, A. M. S., Al-Omar, M. A., Alrashood, K. A. & Habib, E. E. Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1,2,4-triazoline-3-thiones. Eur. J. Med. Chem. 68, 96\u2013102. https:\/\/doi.org\/10.1016\/j.ejmech.2013.07.024 (2013).","journal-title":"Eur. J. Med. Chem."},{"key":"25390_CR38","first-page":"350","volume":"11","author":"HM Hassan","year":"2021","unstructured":"Hassan, H. M., Al-Wahaibi, L. H., Shehatou, G. S. & El-Emam, A. A. Adamantane-linked isothiourea derivatives suppress the growth of experimental hepatocellular carcinoma\u00a0via\u00a0inhibition of TLR4-MyD88-NF-\u03baB signaling. Am. J. Cancer Res. 11, 350\u2013369 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"25390_CR39","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1515\/ncrs-2015-0205","volume":"231","author":"LH Al-Wahaibi","year":"2016","unstructured":"Al-Wahaibi, L. H., Ghabbour, H. A., Mostafa, G. A. E., Almutairi, M. S. & El-Emam, A. A. Crystal structure of 1-(adamantan-1-yl)-3-phenylthiourea, C17H22N2S. Z. Krist. New Crystal Struct. 231, 593\u2013595. https:\/\/doi.org\/10.1515\/ncrs-2015-0205 (2016).","journal-title":"Z. Krist. New Crystal Struct."},{"key":"25390_CR40","doi-asserted-by":"publisher","first-page":"o1523","DOI":"10.1107\/S1600536812017515","volume":"E68","author":"G Demirta\u015f","year":"2012","unstructured":"Demirta\u015f, G. et al. 1-(Adamantan-1-yl)-3-(4-fluorpphenyl)thiourea. Acta Crystallogr. E68, o1523. https:\/\/doi.org\/10.1107\/S1600536812017515 (2012).","journal-title":"Acta Crystallogr."},{"key":"25390_CR41","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1515\/ncrs-2015-0241","volume":"232","author":"FAM Al-Omary","year":"2017","unstructured":"Al-Omary, F. A. M., Ghabbour, H. A., AlRabiah, H., Al-Abdullah, E. S. & El-Emam, A. A. Crystal structure of 1-(adamantan-1-yl)-3-(4-chlorophenyl)thiourea, C17H21ClN2S. Z. Krist. New Crystal Struct. 232, 707\u2013709. https:\/\/doi.org\/10.1515\/ncrs-2015-0241 (2017).","journal-title":"Z. Krist. New Crystal Struct."},{"key":"25390_CR42","unstructured":"Murray, P. R., Baron, E. J., Pfaller, M. A., Tenover, F. C. & Yolken, R. H. in: Wood, G. L. & Washington, J. A. (Eds.). Manual of Clinical Microbiology, Am. Soc. Microbiol., Washington D. C., 1995."},{"key":"25390_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nprot.2007.521","volume":"3","author":"I Wiegand","year":"2008","unstructured":"Wiegand, I., Hilpert, K. & Hancock, R. E. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3, 163\u2013175. https:\/\/doi.org\/10.1038\/nprot.2007.521 (2008).","journal-title":"Nat. Protoc."},{"key":"25390_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/jac\/48.suppl_1.5","volume":"48","author":"JM Andrews","year":"2001","unstructured":"Andrews, J. M. Determination of minimum inhibitory concentrations. J. Antimicrob. Chemother. 48, 5\u201316. https:\/\/doi.org\/10.1093\/jac\/48.suppl_1.5 (2001).","journal-title":"J. Antimicrob. Chemother."},{"key":"25390_CR45","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: Approved standards M100-S27, Wayne, PA, 2018."},{"key":"25390_CR46","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jac\/dkl393","volume":"58","author":"GL French","year":"2006","unstructured":"French, G. L. Bactericidal agents in the treatment of MRSA infections-the potential role of daptomycin. J. Antimicrob. Chemother. 58, 1107\u20131117. https:\/\/doi.org\/10.1093\/jac\/dkl393 (2006).","journal-title":"J. Antimicrob. Chemother."},{"key":"25390_CR47","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1041\/jmb.1905.05022","volume":"29","author":"YJ Song","year":"2019","unstructured":"Song, Y. J., Yu, H. H., Kim, Y. J., Lee, N. K. & Paik, H. D. Anti-biofilm activity of grapefruit seed extract against Staphylococcus aureus and E. coli. J. Microbiol. Biotechnol. 29, 1177\u20131183. https:\/\/doi.org\/10.1041\/jmb.1905.05022 (2019).","journal-title":"J. Microbiol. Biotechnol."},{"key":"25390_CR48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/antibiotics9020059","volume":"9","author":"LK Vestby","year":"2020","unstructured":"Vestby, L. K., Gr\u00f8nseth, T., Simm, R. & Nesse, L. L. Bacterial biofilm and its role in the pathogenesis of disease. Antibiotics 9, 59. https:\/\/doi.org\/10.3390\/antibiotics9020059 (2020).","journal-title":"Antibiotics"},{"key":"25390_CR49","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.284.5418.1318","volume":"284","author":"JW Costerton","year":"1999","unstructured":"Costerton, J. W., Stewart, P. S. & Greenberg, E. P. Bacterial biofilms: A common cause of persistent infections. Science 284, 1318\u20131322. https:\/\/doi.org\/10.1126\/science.284.5418.1318 (1999).","journal-title":"Science"},{"key":"25390_CR50","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55\u201363. https:\/\/doi.org\/10.1016\/0022-1759(83)90303-4 (1983).","journal-title":"J. Immunol. Methods"},{"key":"25390_CR51","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/bioinformatics\/16.8.747","volume":"16","author":"A Lagunin","year":"2000","unstructured":"Lagunin, A., Stepanchikova, A., Filimonov, D. & Poroikov, V. PASS: Prediction of activity spectra for biologically active substances. Bioinformatics 16, 747\u2013748. https:\/\/doi.org\/10.1093\/bioinformatics\/16.8.747 (2000).","journal-title":"Bioinformatics"},{"key":"25390_CR52","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/j.bmcl.2013.03.002","volume":"23","author":"B Gopalan","year":"2013","unstructured":"Gopalan, B. et al. Discovery of adamantane based highly potent HDAC inhibitors. Bioorg. Med. Chem. Lett. 23, 2532\u20132637. https:\/\/doi.org\/10.1016\/j.bmcl.2013.03.002 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"25390_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113338","volume":"217","author":"K Nepali","year":"2021","unstructured":"Nepali, K. et al. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma. Eur. J. Med. Chem. 217, 113338. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113338 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"25390_CR54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejmech.2014.04.021","volume":"79","author":"R Cincinelli","year":"2014","unstructured":"Cincinelli, R. et al. Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors. Eur. J. Med. Chem. 79, 251\u2013259. https:\/\/doi.org\/10.1016\/j.ejmech.2014.04.021 (2014).","journal-title":"Eur. J. Med. Chem."},{"key":"25390_CR55","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1021\/acs.jmedchem.9b01792","volume":"63","author":"SW Zhang","year":"2020","unstructured":"Zhang, S. W. et al. Synthesis and in vitro and in vivo biological evaluation of tissue-specific bisthiazole histone deacetylase (HDAC) inhibitors. J. Med. Chem. 63, 804\u2013815. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01792 (2020).","journal-title":"J. Med. Chem."},{"key":"25390_CR56","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.1021\/acs.jmedchem.1c00491","volume":"64","author":"K Tilekar","year":"2021","unstructured":"Tilekar, K. et al. Thiazolidinedione, \u201cmagic bullets\u201d simultaneously targeting PPAR\u03b3 and HDACs: Design, synthesis, and investigations of their in vitro and in vivo antitumor effects. J. Med. Chem. 64, 6949\u20136971. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00491 (2021).","journal-title":"J. Med. Chem."},{"key":"25390_CR57","doi-asserted-by":"publisher","first-page":"103934","DOI":"10.1016\/j.bioorg.2020.103934","volume":"100","author":"N Upadhyay","year":"2020","unstructured":"Upadhyay, N. et al. Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: In-silico studies, synthesis, and biological evaluation. Bioorg. Chem. 100, 103934. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103934 (2020).","journal-title":"Bioorg. Chem."},{"key":"25390_CR58","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.bmc.2014.01.022","volume":"22","author":"D Secci","year":"2014","unstructured":"Secci, D. et al. Synthesis of a novel series of thiazole-based histone acetyltransferase inhibitors. Bioorg. Med. Chem. 22, 1680\u20131689. https:\/\/doi.org\/10.1016\/j.bmc.2014.01.022 (2014).","journal-title":"Bioorg. Med. Chem."},{"key":"25390_CR59","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1039\/c5ob02250a","volume":"14","author":"F Yang","year":"2016","unstructured":"Yang, F. et al. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities. Org. Biomol. Chem. 14, 1727\u20131735. https:\/\/doi.org\/10.1039\/c5ob02250a (2016).","journal-title":"Org. Biomol. Chem."},{"key":"25390_CR60","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","volume":"13","author":"KJ Falkenberg","year":"2014","unstructured":"Falkenberg, K. J. & Johnstone, R. W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673\u2013791. https:\/\/doi.org\/10.1038\/nrd4360 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"25390_CR61","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1021\/acs.jmedchem.0c01782","volume":"64","author":"XH Zhang","year":"2021","unstructured":"Zhang, X. H. et al. A review of progress in histone deacetylase 6 inhibitors research: Structural specificity and functional diversity. J. Med. Chem. 64, 1362\u20131391. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01782 (2021).","journal-title":"J. Med. Chem."},{"key":"25390_CR62","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","volume":"63","author":"TCS Ho","year":"2020","unstructured":"Ho, T. C. S., Chan, A. H. Y. & Ganesan, A. Thirty years of HDAC inhibitors: 2020 insight and hindsight. J. Med. Chem. 63, 12460\u201312484. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00830 (2020).","journal-title":"J. Med. Chem."},{"key":"25390_CR63","doi-asserted-by":"publisher","first-page":"E2772","DOI":"10.1073\/pnas.1303628110","volume":"110","author":"M Gertz","year":"2013","unstructured":"Gertz, M. et al. Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism. Proc. Natl. Acad. Sci. USA 110, E2772\u2013E2781. https:\/\/doi.org\/10.1073\/pnas.1303628110 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"25390_CR64","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1021\/jm301431y","volume":"56","author":"X Zhao","year":"2013","unstructured":"Zhao, X. et al. The 2.5 \u00c5 crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD+) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition. J. Med. Chem. 56, 963\u2013969. https:\/\/doi.org\/10.1021\/jm301431y (2013).","journal-title":"J. Med. Chem."},{"key":"25390_CR65","unstructured":"Frisch, M. J.,\u00a0Trucks, G. W.,\u00a0Schlegel, H. B.,\u00a0Scuseria, G. E.,\u00a0Robb, M. A.,\u00a0Cheeseman, J. R.;\u00a0Scalmani, G.;\u00a0Barone, V.;\u00a0Mennucci, B.;\u00a0Petersson, G. A.;\u00a0Nakatsuji, H.;\u00a0Caricato, M.;\u00a0Li, X.,\u00a0Hratchian, H. P.,\u00a0Izmaylov, A. F.,\u00a0Bloino, J.,\u00a0Zheng, G.,\u00a0Sonnenberg, J. L.,\u00a0Hada, M.,\u00a0Ehara, M.,\u00a0Toyota, K.,\u00a0Fukuda, R.,\u00a0Hasegawa, J.,\u00a0Ishida, M.,\u00a0Nakajima, T.,\u00a0Honda, Y.,\u00a0Kitao, O.,\u00a0Nakai, H.,\u00a0Vreven, T.,\u00a0Montgomery, J. A. Jr.,\u00a0Peralta, J. E.,\u00a0Ogliaro, F.,\u00a0Bearpark, M. J.,\u00a0Heyd, J.,\u00a0Brothers, E. N.,\u00a0Kudin, K. N.,\u00a0Staroverov, V. N.,\u00a0Kobayashi, R.,\u00a0Normand, J.,\u00a0Raghavachari, K.,\u00a0Rendell, A. P.,\u00a0Burant, J. C.,\u00a0Iyengar, S. S.,\u00a0Tomasi, J.,\u00a0Cossi, M.,\u00a0Rega, N.,\u00a0Millam, N. J.,\u00a0Klene, M.,\u00a0Knox, J. E.,\u00a0Cross, J. B.,\u00a0Bakken, V.,\u00a0Adamo, C.,\u00a0Jaramillo, J.,\u00a0Gomperts, R.,\u00a0Stratmann, R. E.,\u00a0Yazyev, O.,\u00a0Austin, A. J.,\u00a0Cammi, R.,\u00a0Pomelli, C.,\u00a0Ochterski, J. W.,\u00a0Martin, R. L.,\u00a0Morokuma, K.,\u00a0Zakrzewski, V. G.,\u00a0Voth, G. A.,\u00a0Salvador, P.,\u00a0Dannenberg, J. J.,\u00a0Dapprich, S.,\u00a0Daniels, A. D.,\u00a0Farkas, \u00d6.,\u00a0Foresman, J. B.,\u00a0Ortiz, J. V.,\u00a0Cioslowski, J.,\u00a0Fox, D. J.\u00a0Gaussian 09, Revision D.01,\u00a0Gaussian, Inc.,\u00a0Wallingford, CT, USA,\u00a02013."},{"key":"25390_CR66","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem. 31, 455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334 (2010).","journal-title":"J. Comput. Chem."},{"key":"25390_CR67","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","volume":"1263","author":"S Dallakyan","year":"2015","unstructured":"Dallakyan, S. & Olson, A. J. Small-molecule library screening by docking with PyRx. Methods Mol. Biol. 1263, 243\u2013250. https:\/\/doi.org\/10.1007\/978-1-4939-2269-7_19 (2015).","journal-title":"Methods Mol. Biol."},{"key":"25390_CR68","doi-asserted-by":"publisher","first-page":"W530","DOI":"10.1093\/nar\/gkab294","volume":"49","author":"MF Adasme","year":"2021","unstructured":"Adasme, M. F. et al. PLIP 2021: Expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 49, W530\u2013W534. https:\/\/doi.org\/10.1093\/nar\/gkab294 (2021).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25390-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25390-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25390-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T11:10:01Z","timestamp":1670670601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25390-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["25390"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-25390-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"8 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21058"}}